|
1
|
Mehta A and Hughes DA: Fabry Disease. Adam
MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW and Amemiya
A (eds). GeneReviews® Seattle: University of Washington,
Seattle, WA, 1993-2018, 2017.
|
|
2
|
Garman SC and Garboczi DN: The molecular
defect leading to Fabry disease: Structure of human
alpha-galactosidase. J Mol Biol. 337:319–335. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zarate YA and Hopkin RJ: Fabry's disease.
Lancet. 372:1427–1435. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Svarstad E and Marti HP: The changing
landscape of Fabry disease. Clin J Am Soc Nephrol. 15:569–576.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rozenfeld P and Neumann PM: Treatment of
fabry disease: Current and emerging strategies. Curr Pharm
Biotechnol. 12:916–922. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lidove O, West ML, Pintos-Morell G, Reisin
R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C,
Pastores GM and Mehta A: Effects of enzyme replacement therapy in
Fabry disease: A comprehensive review of the medical literature.
Genet Med. 12:668–679. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Keating GM: Agalsidase alfa: A review of
its use in the management of Fabry disease. BioDrugs. 26:335–354.
2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Thurberg BL, Rennke H, Colvin RB, Dikman
S, Gordon RE, Collins AB, Desnick RJ and O'Callaghan M:
Globotriaosylceramide accumulation in the Fabry kidney is cleared
from multiple cell types after enzyme replacement therapy. Kidney
Int. 62:1933–1946. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Khanna R, Soska R, Lun Y, Feng J,
Frascella M, Young B, Brignol N, Pellegrino L, Sitaraman SA,
Desnick RJ, et al: The pharmacological chaperone
1-deoxygalactonojirimycin reduces tissue globotriaosylceramide
levels in a mouse model of Fabry disease. Mol Ther. 18:23–33.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Germain DP, Hughes DA, Nicholls K, Bichet
DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F,
Amartino H, et al: Treatment of Fabry's disease with the
pharmacologic chaperone migalastat. N Engl J Med. 375:545–555.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Modrego A, Amaranto M, Godino A, Mendoza
R, Barra JL and Corchero JL: Human α-galactosidase A mutants:
Priceless tools to develop novel therapies for Fabry disease. Int J
Mol Sci. 22(6518)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Al-Obaide MA, Al-Obaidi II and Vasylyeva
TL: Unexplored regulatory sequences of divergently paired GLA and
HNRNPH2 loci pertinent to Fabry disease in human kidney and skin
cells: Presence of an active bidirectional promoter. Exp Ther Med.
21(154)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ng EK, Leung CP, Shin VY, Wong CL, Ma ES,
Jin HC, Chu KM and Kwong A: Quantitative analysis and diagnostic
significance of methylated SLC19A3 DNA in the plasma of breast and
gastric cancer patients. PLoS One. 6(e22233)2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shaker MM, Shalabi TA and Amr KS:
Correlation of methylation status in MTHFR promoter region with
recurrent pregnancy loss. J Genet Eng Biotechnol.
19(44)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Whybra C, Bähner F and Baron K:
Measurement of disease severity and progression in Fabry disease.
In: Fabry Disease: Perspectives from 5 Years of FOS. Mehta A, Beck
M and Sunder-Plassmann G (eds). Chapter 32. Oxford: Oxford
PharmaGenesis, 2006.
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ashley GA, Shabbeer J, Yasuda M, Eng CM
and Desnick RJ: Fabry disease: Twenty novel alpha-galactosidase A
mutations causing the classical phenotype. J Hum Genet. 46:192–196.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Germain D, Biasotto M, Tosi M, Meo T, Kahn
A and Poenaru L: Fluorescence-assisted mismatch analysis (FAMA) for
exhaustive screening of the alpha-galactosidase A gene and
detection of carriers in Fabry disease. Hum Genet. 98:719–726.
1996.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lukas J, Giese AK, Markoff A, Grittner U,
Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V and
Rolfs A: Functional characterisation of alpha-galactosidase a
mutation as a basis for a new classification system in fabry
disease. PLoS Genet. 9(e1003632)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nakano S, Morizane Y, Makisaka N, Suzuki
T, Togawa T, Tsukimura T, Kawashima I, Sakuraba H and Shibasaki F:
Development of a highly sensitive immuno-PCR assay for the
measurement of α-galactosidase A protein levels in serum and
plasma. PLoS One. 8(e78588)2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rodríguez-Marí A, Coll MJ and Chabás A:
Molecular analysis in Fabry disease in Spain: Fifteen novel GLA
mutations and identification of a homozygous female. Hum Mutat.
22(258)2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shabbeer J, Yasuda M, Benson SD and
Desnick RJ: Fabry disease: Identification of 50 novel
alpha-galactosidase A mutations causing the classic phenotype and
three-dimensional structural analysis of 29 missense mutations. Hum
Genomics. 2:297–309. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Di Risi T, Vinciguerra R, Cuomo M, Della
Monica R, Riccio E, Cocozza S, Imbriaco M, Duro G, Pisani A and
Chiariotti L: DNA methylation impact on Fabry disease. Clin
Epigenetics. 13(24)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Spiegel S, Milstien S and Grant S:
Endogenous modulators and pharmacological inhibitors of histone
deacetylases in cancer therapy. Oncogene. 31:537–551.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Silva GD, Coeli-Lacchini FB and Leopoldino
AM: How do sphingolipids play a role in epigenetic mechanisms and
gene expression? Epigenomics. 14:219–222. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Meyer KD, Saletore Y, Zumbo P, Elemento O,
Mason CE and Jaffrey SR: Comprehensive analysis of mRNA methylation
reveals enrichment in 3' UTRs and near stop codons. Cell.
149:1635–1646. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Magg B, Riegler C, Wiedmann S, Heuschmann
P, Sommer C and Üçeyler N: Self-administered version of the
Fabry-associated pain questionnaire for adult patients. Orphanet J
Rare Dis. 10(113)2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gibas AL, Klatt R, Johnson J, Clarke JT
and Katz J: A survey of the pain experienced by males and females
with Fabry disease. Pain Res Manag. 11:185–192. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Crosbie TW, Packman W and Packman S:
Psychological aspects of patients with Fabry disease. J Inherit
Metab Dis. 32:745–753. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tabira T, Goto I, Kuroiwa Y and Kikuchi M:
Neuropathological and biochemical studies in Fabry's disease. Acta
Neuropathol. 30:345–354. 1974.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gadoth N and Sandbank U: Involvement of
dorsal root ganglia in Fabry's disease. J Med Genet. 20:309–312.
1983.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Miller JJ, Aoki K, Moehring F, Murphy CA,
O'Hara CL, Tiemeyer M, Stucky CL and Dahms NM: Neuropathic pain in
a Fabry disease rat model. JCI Insight. 3(e99171)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Rajan JN, Ireland K, Johnson R and Stepien
KM: Review of mechanisms, pharmacological management, psychosocial
implications, and holistic treatment of pain in Fabry disease. J
Clin Med. 10(4168)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Donaldson LF and Beazley-Long N:
Alternative RNA splicing: Contribution to pain and potential
therapeutic strategy. Drug Discov Today. 21:1787–1798.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
de la Peña JB and Campbell ZT:
RNA-binding proteins as targets for pain therapeutics. Neurobiol
Pain. 4:2–7. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Song KY, Choi HS, Law PY, Wei LN and Loh
HH: Post-transcriptional regulation of mu-opioid receptor: Role of
the RNA-binding proteins heterogeneous nuclear ribonucleoprotein H1
and F. Cell Mol Life Sci. 69:599–610. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Alkan SA, Martincic K and Milcarek C: The
hnRNPs F and H2 bind to similar sequences to influence gene
expression. Biochem J. 393:361–371. 2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lev Maor G, Yearim A and Ast G: The
alternative role of DNA methylation in splicing regulation. Trends
Genet. 31:274–280. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Al-Obaide MA and Vasylyeva TL: The
Knockdown of RPL36A downregulates GLA expression associated with
Fabry disease in vitro model. ASN ePosters. (Abstract
PO1600)2020.
|
|
41
|
Kim JH, You KR, Kim IH, Cho BH, Kim CY and
Kim DG: Over-expression of the ribosomal protein L36a gene is
associated with cellular proliferation in hepatocellular carcinoma.
Hepatology. 39:129–138. 2004.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Xu M, Wang Y, He HT and Yang Q: MiR-589-5p
is a potential prognostic marker of hepatocellular carcinoma and
regulates tumor cell growth by targeting MIG-6. Neoplasma.
65:753–761. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Happle R: X-chromosome inactivation: Role
in skin disease expression. Acta Paediatr Suppl. 95:16–23.
2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dobyns WB: The pattern of inheritance of
X-linked traits is not dominant or recessive, just X-linked. Acta
Paediatr Suppl. 95:11–15. 2006.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Rozenfeld PA: Fabry disease: Treatment and
diagnosis. IUBMB Life. 61:1043–1050. 2009.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Weingarten-Gabbay S, Nir R, Lubliner S,
Sharon E, Kalma Y, Weinberger A and Segal E: Systematic
interrogation of human promoters. Genome Res. 29:171–183.
2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Fan S, Wang L, Liang L, Cao X, Tang J and
Tian Q: The progress on the estimation of DNA methylation level and
the detection of abnormal methylation. Quant Biol. 10:55–66.
2022.
|
